| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802471903259 | 247190325 | DALZAD F.C.TAB 80MG/TAB BTx14 (BLIST1x14) (PVC/PVDC/ALU ημερολογιακά) (PVC/PVDC/ALU ημερολογιακά) | 2.64 | 2.77 | 3.82 |
| 05/2018 | 2802471904256 | 247190425 | DALZAD F.C.TAB 160MG/TAB BTx14 (BLIST1x14) (PVC/PVDC/ALU ημερολογιακά) (PVC/PVDC/ALU ημερολογιακά) | 03.06 | 3.21 | 4.42 |
| 05/2018 | 2802471905253 | 247190525 | DALZAD F.C.TAB 40MG/TAB BTx14 (BLIST1x14) (PVC/PVDC/ALU ημερολογιακά) (PVC/PVDC/ALU ημερολογιακά) | 3.15 | 3.30 | 4.55 |
| 05/2018 | 2802471906021 | 247190602 | DALZAD F.C.TAB 320MG/TAB BTx14 (BLIST 1x14) (PVC/PE/PVDC/ALU) (PVC/PE/PVDC/ALU) | 5.45 | 5.71 | 7.87 |
| 05/2018 | 2802471906281 | 247190628 | DALZAD F.C.TAB 320MG/TAB BTx14 [BLIST1x14 (PVC/PVDC/ALU ημερολογιακά)] [BLIST1x14 (PVC/PVDC/ALU ημερολογιακά)] | 5.42 | 5.69 | 7.84 |
For the treatment of hypertension.
Valsartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Absolute bioavailability = 23% with high variability
The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.
* 17 L
* 2 L/h [IV administration] * 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]